PPBT Purple Biotech

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Kitov Pharmaceutical Holdings Ltd.

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Kitov Pharmaceutical Holdings Ltd. (NASDAQ: KTOV) resulting from allegations that Kitov may have issued materially misleading business information to the investing public.

On February 6, 2017, the Israeli publication Calcalist reported that Kitov’s Chief Executive Officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority on suspicion of publishing misleading information in connection with a recent clinical trial of one of Kitov’s products. On this news, shares of Kitov fell $0.33 per share or over 11%, to close at $2.55 per share on February 6, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Kitov investors. If you purchased shares of Kitov before February 6, 2017 please visit the firm’s website at http://www.rosenlegal.com/cases-1051.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
06/02/2017

Underlying

PPBTPurple Biotech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Purple Biotech

 PRESS RELEASE
Free
PPBT PURPLE BIOTECH

Kitov Announces Name Change to Purple Biotech Ltd.

Kitov Announces Name Change to Purple Biotech Ltd. New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has changed its corporate name from Kitov Pharma Ltd. to Purple Biotech Ltd. The name change will be effective for trading purposes on the Tel Aviv Stock Exchange (TASE) and the NASDAQ Capital Market (NASDA...

December 10, 2020 1 EN
 PRESS RELEASE
Free
PPBT PURPLE BIOTECH

Kitov Pharma to Participate in November Investor Conferences

Kitov Pharma to Participate in November Investor Conferences TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that management will present at the H.C. Wainwright 6th Annual Israel Conference and will participate in one-on-one meetings at the Jefferies Virtual London Healthcare Conference. H.C. Wainwright 6th Annual Israel Conference                 Date:                 Thursday, November 12, 2020           ...

November 11, 2020 1 EN
 PRESS RELEASE
Free
PPBT PURPLE BIOTECH

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Ce...

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that t...

November 9, 2020 1 EN
 PRESS RELEASE
Free
PPBT PURPLE BIOTECH

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering i...

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219 Patent covers NT219’s combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®) TEL AVIV, Israel, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled “Combination...

October 27, 2020 1 EN
 PRESS RELEASE
Free
PPBT PURPLE BIOTECH

New Mechanism of Action Data for NT219 Presented at Epigenetics and Me...

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced new data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3 is being presented  in a  video recorded presentation at the E...

October 16, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch